Search research articles
Contact Us
Filters
Showing results (601-610 of 692) with videos related to
Page
of 70
Sort By:
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
JAMA Oncology
|
November 10, 2017
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
Josef J Fox, Somali C Gavane, Estelle Blanc-Autran, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
European Urology
|
February 7, 2012
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index
David Ulmert, Reza Kaboteh, Josef J Fox, et al.
NPJ Precision Oncology
|
February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
Charlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Konrad H Stopsack, Subhiksha Nandakumar, Kanika Arora, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Page
of 70
Search research articles
Search
Showing results (601-610 of 692) with videos related to
Sort By:
Page
of 70
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
JAMA Oncology
|
November 10, 2017
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
Josef J Fox, Somali C Gavane, Estelle Blanc-Autran, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
European Urology
|
February 7, 2012
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index
David Ulmert, Reza Kaboteh, Josef J Fox, et al.
NPJ Precision Oncology
|
February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
Charlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Konrad H Stopsack, Subhiksha Nandakumar, Kanika Arora, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Page
of 70